Trials / Completed
CompletedNCT00433095
Vinorelbine (Oral) Plus Trastuzumab for 1st-line Treatment of HER2/Neu Overexpressing Breast Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- Ludwig-Maximilians - University of Munich · Academic / Other
- Sex
- Female
- Age
- 18 Years – 75 Years
- Healthy volunteers
- —
Summary
1st-line treatment of HER2/neu overexpressing breast cancer
Detailed description
The combination of vinorelbine and trastuzumab was demonstrated to be highly effective in several trials showing response rates in the range of 59-78%. This combination is characterized by good tolerability and can be applied for a prolonged period without the risk of major cumulative toxicity The availability of oral vinorelbine promises a further simplification of therapy. The present trial therefore investigates the safety and efficacy of a combined treatment with trastuzumab and oral vinorelbine.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Navelbine | |
| DRUG | Herceptin | |
| DRUG | Navelbine (oraly) |
Timeline
- First posted
- 2007-02-09
- Last updated
- 2011-03-14
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT00433095. Inclusion in this directory is not an endorsement.